Astrana Health (NASDAQ:ASTH) Now Covered by TD Cowen

TD Cowen assumed coverage on shares of Astrana Health (NASDAQ:ASTH) in a report published on Monday morning, MarketBeat Ratings reports. The brokerage issued a buy rating and a $66.00 target price on the stock.

A number of other brokerages also recently weighed in on ASTH. Truist Financial boosted their price target on Astrana Health from $50.00 to $59.00 and gave the stock a buy rating in a research report on Friday, August 9th. BTIG Research increased their price target on Astrana Health from $60.00 to $70.00 and gave the company a buy rating in a research note on Thursday, October 3rd. KeyCorp began coverage on Astrana Health in a report on Friday. They set a sector weight rating for the company. Stifel Nicolaus upped their price objective on shares of Astrana Health from $48.00 to $60.00 and gave the company a buy rating in a report on Thursday, August 1st. Finally, Robert W. Baird raised their target price on shares of Astrana Health from $54.00 to $67.00 and gave the stock an outperform rating in a research note on Thursday, August 15th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Astrana Health currently has a consensus rating of Buy and a consensus price target of $62.00.

Astrana Health Price Performance

NASDAQ:ASTH opened at $59.64 on Monday. The stock has a market capitalization of $3.34 billion, a PE ratio of 45.18, a P/E/G ratio of 2.20 and a beta of 1.21. Astrana Health has a 1-year low of $28.86 and a 1-year high of $61.51. The firm has a fifty day simple moving average of $52.01 and a 200 day simple moving average of $45.34. The company has a current ratio of 1.84, a quick ratio of 1.84 and a debt-to-equity ratio of 0.62.

Astrana Health (NASDAQ:ASTH) last announced its quarterly earnings data on Wednesday, August 7th. The company reported $0.40 EPS for the quarter, beating analysts’ consensus estimates of $0.39 by $0.01. The company had revenue of $486.30 million during the quarter, compared to the consensus estimate of $440.68 million. Astrana Health had a net margin of 4.30% and a return on equity of 10.71%. The company’s quarterly revenue was up 39.7% on a year-over-year basis. During the same quarter last year, the firm posted $0.28 EPS. On average, research analysts expect that Astrana Health will post 1.33 EPS for the current fiscal year.

Institutional Trading of Astrana Health

A number of institutional investors have recently bought and sold shares of ASTH. GAMMA Investing LLC acquired a new stake in shares of Astrana Health in the third quarter valued at approximately $34,000. Central Pacific Bank Trust Division bought a new position in Astrana Health during the 3rd quarter worth $160,000. Granite Bay Wealth Management LLC acquired a new position in Astrana Health in the 3rd quarter valued at $290,000. Handelsbanken Fonder AB bought a new stake in shares of Astrana Health during the 3rd quarter valued at $492,000. Finally, SG Americas Securities LLC acquired a new stake in shares of Astrana Health during the 3rd quarter worth $680,000. Institutional investors own 52.77% of the company’s stock.

About Astrana Health

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.